Advocates for psychedelics have cast a concerned glance at the news that the leader in the field, Compass Pathways, has again pushed back pivotal data readouts for its treatment-resistant depression (TRD) candidate and announced plans to slash its staff by 30%.
Shares in London, UK-headquartered Compass, which is listed on the NASDAQ and has offices in New York and San Francisco, closed down by 23% at $4.76 on 31 October following a disappointing third-quarter business update. The company revealed that the company will shift the topline data readout from a Phase III trial (called COMP005) of its psilocybin-based TRD therapy,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?